thymosin beta-4 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-26. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
== Other salvage pathways == L-methionine salvage is the pathway that regenerates methionine from its downstream products. A version of the pathway uses methylthioadenosine (MTA), forming the so-called MTA cycle with its synthesizing reaction. This sulphur-recycling action is found in humans, and seems to be universal among aerobic life. Nicotinate salvage is the process of regenerating nicotinamide adenine dinucleotide from nicotinic acid. This pathway is important for controlling the level of oxidative stress in cells. The human gene NAPRT encodes the main enzyme in the pathway. Cancer cells, which have increased NAD requirements, tend to upregulate the pathway. Salvage pathways also exist for ceramide, cobalamin, cell wall components, and tetrahydrobiopterin in various organisms.
Schleswig-Holstein lies on the base of Jutland Peninsula between the North Sea and the Baltic Sea. Strictly speaking, "Schleswig" refers to the German Southern Schleswig (German: Südschleswig or Landesteil Schleswig, Danish: Sydslesvig), whereas Northern Schleswig is in Denmark (South Jutland County, Region of Southern Denmark). The state of Schleswig-Holstein further consists of Holstein, as well as Lauenburg and the formerly independent city of Lübeck. Schleswig-Holstein borders Denmark (Southern Denmark) to the north, the North Sea to the west, the Baltic Sea to the east, and the German states of Lower Saxony, Hamburg, and Mecklenburg-Vorpommern to the south. In the western part of the state, the lowlands have virtually no hills. The North Frisian Islands, as well as almost all of Schleswig-Holstein's North Sea coast, form the Schleswig-Holstein Wadden Sea National Park (Nationalpark Schleswig-Holsteinisches Wattenmeer), which is the largest national park in Central Europe. The Baltic Sea coast in the east of Schleswig-Holstein is marked by bays, fjords, and cliff lines. Rolling hills (the highest elevation is the Bungsberg at 168 metres or 551 feet) and many lakes are found, especially in the eastern part of Holstein called the Holstein Switzerland and the former Duchy of Lauenburg (Herzogtum Lauenburg). The longest river besides the Elbe is the Eider. Among the states of Germany, Schleswig-Holstein has the least area covered by forest, 11%, which is less than in the city-states of Hamburg and Bremen. (The national average is 32%).
=== Copolymers and modified polymers === Linear polyacrylamide is a water-soluble polymer. Other polar solvents include DMSO and various alcohols. Cross-linking can be introduced using N,N-methylenebisacrylamide. Some crosslinked materials are swellable but not soluble, i.e., they are hydrogels. Partial hydrolysis occurs at elevated temperatures in aqueous media, converting some amide substituents to carboxylates. This hydrolysis thus makes the polymer particularly hydrophilic. The polymer produced from N,N-dimethylacrylamide resists hydrolysis. Copolymers of acrylamide include those derived from acrylic acid.
Sources: en.wikipedia.org
The use of gas turbines to blast a large volume of high velocity water proved popular with firefighters for stubborn fires. A Hungarian team used a converted T-34 tank with two MiG-21 engines mounted to the turret to extinguish 9 fires in 43 days. The machine was known as Big Wind. In fighting a fire at a directly vertical spewing wellhead, high explosives, such as dynamite were used to create a blast wave that pushes the burning fuel and local atmospheric oxygen away from the well. (This is a similar principle to blowing out a candle.) The flame is removed and the fuel can continue to spill out without igniting. Generally, explosives were placed within 55 gallon drums, the explosives surrounded by fire retardant chemicals, and then the drums are wrapped with insulating material with a horizontal crane being used to bring the drum as close to the burning area as possible. The firefighting teams titled their occupation as "Operation Desert Hell" after Operation Desert Storm.
Citrus greening disease (Chinese: 黃龍病; pinyin: huánglóngbìng abbr. HLB) is a disease of citrus trees caused by bacteria of the genus Liberibacter. These microbes are transmitted by two species of bug: the Asian citrus psyllid Diaphorina citri and the African citrus psyllid Trioza erytreae. It has no known cure. It is graft-transmissible. There are three different types of the disease: a heat-tolerant Asian form, and the heat-sensitive African and American forms. It was first described and reported in southern China in 1919. The African variation was first reported in 1937 in South Africa, where it is still widespread. It reached Florida in 2005, and within three years had spread to the majority of citrus farms. The rapid increase in this disease has threatened the citrus industry in the entire US. As of 2009, 33 countries had reported the infection in their citrus crop.
== History == The FODMAP concept was first published in 2005. In this paper, it was proposed that a collective reduction in the dietary intake of all indigestible or slowly absorbed, short-chain carbohydrates would minimize stretching of the intestinal wall. This was proposed to reduce stimulation of the gut's nervous system and provide the best chance of reducing symptom generation in people with IBS (see below). At the time, there was no collective term for indigestible or slowly absorbed, short-chain carbohydrates, so the term FODMAP was created to improve understanding and facilitate communication of the concept. The low-FODMAP diet was originally developed by a research team at Monash University in Melbourne, Australia. The Monash team undertook the first research to investigate whether a low-FODMAP diet improved symptom control in patients with IBS and established the mechanism by which the diet exerted its effect. Monash University also established a rigorous food analysis program to measure the FODMAP content of a wide selection of Australian and international foods. The FODMAP composition data generated by Monash University updated previous data that was based on limited literature, with guesses (sometimes wrong) made where there was little information.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.